51
|
Danne T, Kaltheuner M, Koch A, Ernst S, Rathmann W, Rüssmann HJ, Bramlage P. ["DIabetes Versorgungs-Evaluation" (DIVE)--a national quality assurance initiative at physicians providing care for patients with diabetes]. Dtsch Med Wochenschr 2013; 138:934-9. [PMID: 23613371 DOI: 10.1055/s-0033-1343144] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
Abstract
BACKGROUND Due to the variety of affected organ systems, necessitating a multidisciplinary and interconnected approach in deciding on individual diagnostic and therapeutic strategies, a structured documentation of data for patients suffering from diabetes mellitus is steadily gaining importance. Towards this purpose, multiple quality initiatives (e. g. SWEET, QS-DPV, EUBIROD etc.) as well as several software systems (e. g. [DPV2] DIAMAX, DPV, EMIL, Qmax etc.) have been developed to capture patient-related data. This is further complicated by the necessity to exchange data with a large variety of doctor's office administration systems. METHODS To address this complex of issues, DiabetesDE in cooperation with several societies, doctor's associations and prospective end users launched a national register platform. DIVE (Diabetes Care Evaluation) is aimed at establishing a national diabetes register to centrally capture data from diabetes patients being treated by diabetology specialists in Germany, thus making them available for quality assurance and health services research. RESULTS Since September 2011, 142 so far participating doctors have documented data for 84,774 patients. Compared to patients treated by general practitioners, persons under specialist care show a more advanced clinical picture with substantial co-morbidity. CONCLUSION DIVE provides a national platform which will address essential fields of activity with regard to the development of a national diabetes strategy--epidemiology, diabetes registry, health care research, quality assurance--based on usual office administration systems, thus contributing to the improvement of care and treatment for patients suffering from diabetes.
Collapse
|
52
|
Seufert J, Siegmund T, Bramlage P, Brath H. Unabhängige Prädiktoren hypoglykämischer Ereignisse bei Patienten mit Typ-2 Diabetes unter einer Kombinationstherapie mit Insulin glargin, oralen Antidiabetika und einem singulären Bolus Insulin glulisin (BOT-Plus). DIABETOL STOFFWECHS 2013. [DOI: 10.1055/s-0033-1341783] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
53
|
Tschöpe D, Bramlage P, Binz C, Krekler M, Schneider S, Gitt AK. Prognostische Bedeutung von Hypoglykämien für Patienten mit Typ-2 Diabetes - Ergebnisse der Nachbeobachtung von DiaRegis über 2 Jahre. DIABETOL STOFFWECHS 2013. [DOI: 10.1055/s-0033-1341786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
54
|
Weber D, Bramlage P, Kaltheuner M, Ernst S, Koch A, Danne T. Versorgung von Patienten mit Typ-2 Diabetes in diabetologischen Schwerpunktpraxen in Deutschland - erste Ergebnisse der Diabetes Versorgungs-Evaluation (DIVE). DIABETOL STOFFWECHS 2013. [DOI: 10.1055/s-0033-1341883] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
55
|
Tschöpe D, Bramlage P, Binz C, Krekler M, Schneider S, Gitt AK. Bedeutung von anti-diabetischen Behandlungsentscheidungen nach Versagen einer Metformin Monotherapie im Hinblick auf Blutzuckerkontrolle und Prognose - Ergebnisse der Nachbeobachtung von DiaRegis über 2 Jahre. DIABETOL STOFFWECHS 2013. [DOI: 10.1055/s-0033-1341776] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
56
|
Tschöpe D, Schmieder RE, Duetting E, Bramlage P, Schneider S, Gitt AK. Zielwerterreichung für Blutzucker- und Blutdruckeinstellung bei Patienten mit Typ-2 Diabetes und Hypertonie im klinischen Alltag - Rationale und Design des DIALOGUE Registers. DIABETOL STOFFWECHS 2013. [DOI: 10.1055/s-0033-1341886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
57
|
Schmieder R, Bramlage P. Diagnostik, Bedeutung, Prävention und Therapie einer Mikroalbuminurie - Erwiderung. Dtsch Med Wochenschr 2012. [DOI: 10.1055/s-0032-1327216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
58
|
Schymik G, Herbinger T, Wuerth A, Schymik JS, Bramlage P, Heimeshoff M, Sueselbeck T, Kiefer R, Gonska BD, Posival H, Schmitt C, Schroefel H. TCT-887 TAVR– 3 year results of transapical versus transfemoral approach in a real world population of 1000 patients with severe aortic stenosis. J Am Coll Cardiol 2012. [DOI: 10.1016/j.jacc.2012.08.933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
59
|
Schmieder R, Bramlage P. Diagnostik, Bedeutung, Prävention und Therapie einer Mikroalbuminurie. Dtsch Med Wochenschr 2012; 137:1409-16; quiz 1417-8. [DOI: 10.1055/s-0032-1305058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
60
|
Bukowska A, Hammwöhner M, Sixdorf A, Schild L, Wiswedel I, Röhl FW, Wolke C, Lendeckel U, Aderkast C, Bochmann S, Chilukoti RK, Mostertz J, Bramlage P, Goette A. Dronedarone prevents microcirculatory abnormalities in the left ventricle during atrial tachypacing in pigs. Br J Pharmacol 2012; 166:964-80. [PMID: 22103242 PMCID: PMC3417422 DOI: 10.1111/j.1476-5381.2011.01784.x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2010] [Revised: 11/02/2011] [Accepted: 11/09/2011] [Indexed: 02/02/2023] Open
Abstract
BACKGROUND AND PURPOSE Atrial fibrillation induces ischaemic microcirculatory flow abnormalities in the ventricle, contributing to the risk for acute coronary syndromes. We evaluated the effect of dronedarone on ventricular perfusion during rapid atrial pacing (RAP). EXPERIMENTAL APPROACH Coronary and fractional flow reserve (CFR/FFR) were measured in the left anterior descending artery in 29 pigs. Six received RAP, six received RAP with dronedarone (RAP/D), seven received dronedarone alone, four received RAP with amiodarone (RAP/A), and six received neither (sham). In ventricular tissue, oxidative stress/ischaemia-related gene and protein expression was evaluated by RT-PCR and Western blotting; Isoprostanes were measured by GC-MS procedures. KEY RESULTS CFR was decreased in the RAP group, compared with other groups. FFR was not different between groups. Effective refractory period was reduced in RAP compared with RAP/D. RAP-activated PKC phosphorylation tended to be decreased by dronedarone (P= 0.055) RAP induced NOX-1 and NOX-2 protein and the mRNA for hypoxia-inducible factor-1α (HIF-1α). Dronedarone reduced the pacing-dependent increase in the expression of NOX-2 protein and of HIF-1α mRNA. The oxidative stress marker, F(2)-isoprostane, was increased by RAP and this increase was attenuated by dronedarone. Other oxidative stress/ischaemia-related genes were induced by RAP compared with sham and were decreased by dronedarone treatment. In HL1 cells, dronedarone significantly inhibited the increased phosphorylation of PKCα after oxidative stress, with an almost significant effect (P= 0.059) on that after RAP. CONCLUSIONS AND IMPLICATIONS Dronedarone abolished RAP-induced ventricular microcirculatory abnormalities by decreasing oxidative stress/ischaemia-related gene and protein expression in the ventricle.
Collapse
|
61
|
Tschöpe D, Bramlage P, Binz C, Krekler M, Deeg E, Gitt A. DPP-4 Hemmer im Vergleich zu Sulfonylharnstoffen zusätzlich zu Metformin im klinischen Alltag - Ergebnisse der Nachbeobachtung des prospektiven DiaRegis Registers über 1 Jahr. DIABETOL STOFFWECHS 2012. [DOI: 10.1055/s-0032-1314555] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
62
|
Halle M, Gitt AK, Hanefeld M, Kellerer M, Marx N, Meier JJ, Schumm-Draeger PM, Bramlage P, Tschoepe D. [Diabetes and heart failure: a practically oriented critical appraisal]. Dtsch Med Wochenschr 2012; 137:437-41. [PMID: 22354800 DOI: 10.1055/s-0031-1298982] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
Patients with type 2 diabetes have an increased risk for developing symptoms of heart failure. These can be accompanied by a reduction of left ventricular ejection fraction (HFREF, systolic heart failure) or by a preserved function (HFPEF, diastolic heart failure). The pathophysiology of both entities is distinct and involves impairment of myocardial metabolism and coronary circulation alike. Although diabetes and heart failure often coincide, the management of these patients particularly with respect to the specific benefits or possible hazards of antidiabetic treatment is vague. Therefore, from a pathophysiological as well as clinical viewpoint, 1) diabetic patients with symptoms of heart failure have to be differentiated regarding systolic as well as diastolic left ventricular function by echocardiography and tissue doppler imaging. 2) Heart failure in diabetic patients needs similar attention due to a prognosis and interactions. 3) Optimized blood glucose lowering in combination with improvement of other cardiovascular risk factors is evident for HFREF and is assumed to be beneficial for HFPEF. 4) Antidiabetic medication has to be specifically adapted for both entities. As prospective, controlled studies are scarce, future interventional studies should specifically focus on clinical outcome in diabetic patients with different entities of heart failure.
Collapse
|
63
|
Schmieder RE, Bramlage P, Schunkert H. [Chronobiology of blood pressure and chronopharmacotherapy of arterial hypertension]. Dtsch Med Wochenschr 2012; 137:317-21. [PMID: 22318846 DOI: 10.1055/s-0031-1298845] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
Abstract
Arterial blood pressure is subject to a circadian rhythm that results in a fall of blood pressure during the night. In patients with diabetes, renal insufficiency, left-ventricular hypertrophy, sleep apnea, hypertension of pregnancy, and different forms of secondary hypertension a nocturnal fall of blood pressure is even abandoned or reverted. Diagnosis is made using 24-h blood pressure measurement, which is however used not frequently enough for a clinical assessment or adjustment of therapy. An adaption of the selection or the time of administration of antihypertensive drugs with respect to the circadian rhythm is beneficial to control blood pressure and reduce cardiovascular morbidity. This is particularly true for patients with an a non- or inverted dipping blood pressure pattern, in which the bedtime dosing may result in a normalization of blood pressure and restoration of a normal circadian rhythm. The present manuscript reviews the chronopharmacotherapy of arterial hypertension and grant practical recommendations for their translation into clinical practice.
Collapse
|
64
|
Thoenes M, Spirk D, Böhm M, Mahfoud F, Thevathasan L, Bramlage P. Treatment of hypertension in the elderly: data from an international cohort of hypertensives treated by cardiologists. J Hum Hypertens 2012; 27:131-7. [PMID: 22258208 DOI: 10.1038/jhh.2011.114] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Hypertension in the elderly is a major risk factor for cardiovascular disease. We aimed to analyze determinants of blood pressure (BP) control across different age groups. Population of a large global survey on hypertension treatment and control including 18927 patients was analyzed. A logistic regression analysis was conducted to estimate BP control rates and the prevalence of antihypertensive drug usage according to age. Systolic BP control decreased from 29.6% (95% confidence intervals (CI) 26.0;33.5) at 18-40 years to 22.4% (20.8;24.2) at >75 years (P<0.0001), and diastolic BP control increased from 31.6% (27.9;35.6) to 57.3% (55.2;59.3), respectively (P<0.0001). BP control was worse in diabetic patients, but did not differ substantially with co-morbid conditions, except for a better control in patients with myocardial infarction (MI) (P<0.05). The use of ≥ 3 antihypertensive drugs increased with age from 16.1 to 37.8% (P<0.0001) due to a more frequent use of loop diuretics (P<0.0001), thiazides (P<0.0001), angiotensin-converting enzyme (ACE) inhibitors (P<0.0001) and calcium channel blockers (P<0.0001). About one third of patients received non-guideline-recommended drug-drug combinations. BP control is largely unsuccessful with increasing age. Owing to frequent inadequacies in the combination of antihypertensive drugs, future guidelines and educational programs should devote increased attention to the choice of optimal drug-drug combinations in the elderly.
Collapse
|
65
|
Bohm M, Reil JC, Bramlage P, Pitt B, Zannad F. Clinical efficacy of aldosterone-blocking agents. Eur Heart J Suppl 2011. [DOI: 10.1093/eurheartj/sur002] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
66
|
Zannad F, Ketelslegers JM, Bramlage P. Role of biomarkers in guiding treatment with aldosterone-blocking agents. Eur Heart J Suppl 2011. [DOI: 10.1093/eurheartj/sur003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
67
|
Bramlage P, Turgonyi E, Montalescot G. Aldosterone blockade: current research and future trends. Eur Heart J Suppl 2011. [DOI: 10.1093/eurheartj/sur005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
|
68
|
Schellong SM, Gerlach HE, Tebbe U, Haas S, Melzer N, Abletshauser C, Sieder C, Bramlage P, Riess H, Bauersachs R. Certoparin versus UFH to prevent venous thromboembolic events in the very elderly patient: an analysis of the CERTIFY study. Thromb Res 2011; 128:417-21. [PMID: 21658750 DOI: 10.1016/j.thromres.2011.05.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2011] [Revised: 04/26/2011] [Accepted: 05/02/2011] [Indexed: 10/18/2022]
Abstract
INTRODUCTION There is an exponential rise of thromboembolic risk with age because of co-morbidities, immobility and pharmacotherapy. We aimed to investigate the benefits and risks of heparin prophylaxis in very elderly patients ≥80 years and the type of heparin used in a subgroup analysis of the CERTIFY trial. PATIENTS/METHODS 3,239 patients were randomized to 3,000 U aXa o.d. certoparin or 5,000 IU t.i.d. unfractionated heparin (UFH) for 8-20 days. RESULTS Patients ≥80 years (n=1,365) were more likely to be female, had a lower mean bodyweight, were more frequently using antiplatelets and had a GFR below 30 ml/min/1.73 m(2) more often than patients <80 years (n=1,875). The combined endpoint of proximal DVT, symptomatic non-fatal PE and VTE related death was experience by 5.26% of patients ≥80 years versus 3.51% in younger patients (OR 1.53; 95%CI 1.05-2.21; p=0.03). There were no significant differences in both minor (OR 1.11; 95%CI 0.75-1.62) and major (OR 2.53; 95%CI 0.93-6.86) bleeding risks. Certoparin and UFH were equally effective in reducing thromboembolic risk in either age group. The risk of any (OR 0.45; 95%CI 0.26-0.79) and minor bleeding (OR 0.42; 95%CI 0.23-0.78) was reduced with certoparin in the very elderly only. There were more adverse events in elderly patients (OR 1.26; 95%CI 1.1-1.46), but rates were otherwise comparable. CONCLUSIONS The analysis confirmed the increased thromboembolic risk in very elderly patients, but demonstrated no increased bleeding risk. Certoparin and UFH were equally effective and safe with a reduced risk of minor bleeding complications with certoparin in the very elderly.
Collapse
|
69
|
Tschöpe D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Gitt A. Typ-2 Diabetes und Hypogylkämien bei älteren Patienten –6-Monats Follow-up Ergebnisse des prospektiven DiaRegis Registers. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277424] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
70
|
Tschöpe D, Binz C, Bramlage P, Krekler M, Plate T, Deeg E, Gitt A. Komorbidität und inzidente Hypoglykämien bei Patienten mit Typ-2 Diabetes und Herzinsuffizienz –6-Monats Follow-up Ergebnisse des prospektiven DiaRegis Registers. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
71
|
Tschöpe D, Bramlage P, Binz C, Krekler M, Plate T, Deeg E, Gitt A. Typ-2 Diabetes und Hypoglykämien –6-Monats Follow-up Ergebnisse des prospektiven DiaRegis Registers. DIABETOL STOFFWECHS 2011. [DOI: 10.1055/s-0031-1277425] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
72
|
Bauersachs R, Schellong SM, Haas S, Tebbe U, Gerlach HE, Abletshauser C, Sieder C, Melzer N, Bramlage P, Riess H. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost 2011; 105:981-8. [PMID: 21505722 DOI: 10.1160/th10-09-0614] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2010] [Accepted: 03/05/2011] [Indexed: 11/05/2022]
Abstract
Patients with severe renal insufficiency (sRI) have been suggested to be at an increased risk of bleeding with low-molecular-weight heparins (LMWH). We aimed at assessing the benefits and risks of certoparin in comparison to unfractionated heparin (UFH) in these patients. In this subgroup analysis of the CERTIFY trial, acutely ill, non-surgical patients ≥70 years received certoparin 3,000U aXa o.d. or UFH 5,000 IU t.i.d. One hundred eighty-nine patients had a glomerular filtration rate (GFR) ≤30 ml/min/1.73 m2, 3,050 patients served as controls. Patients with sRI had a mean age of 85.9 ± 6.6 years (controls 78.4 ± 6.0) and were treated for a mean of 9.3 ± 3.7 days (9.9 ± 4.3). Thromboembolic event rates were comparable (4.55 vs. 4.21%; OR1.08; 95%CI 0.5-2.37) but bleeding was increased in sRI (9.52 vs. 3.54%; OR2.87; 95%CI 1.70-4.83). The incidence of the combined end-point of proximal DVT, symptomatic non-fatal PE and VTE related death was 6.49% with certoparin and 2.60% with UFH (OR2.60; 95%CI 0.49-13.85). There was a decrease in total bleeding with certoparin (OR0.33; 95%CI 0.11-0.97), which was non-significant in patients with GFR >30 ml/min/1.73 m2. In two multivariable regression models certoparin and immobilisation <10 days were associated with less bleeding while a GFR ≤30 ml/min/1.73 m2 was associated with increased bleeding. A total of 11.3% of certoparin- and 18.5% of UFH-treated patients experienced serious adverse events (14.8 in patients with a GFR ≤30 vs. 5.6% vs. >30 ml/min/1.73 m2). In conclusion, certoparin 3,000U anti Xa o.d. was as efficacious as 5,000 IU UFH t.i.d. in patients with sRI but had a reduced risk of bleeding.
Collapse
|
73
|
Bramlage P, Wolf WP, Fronk EM, Stuhr T, Erdlenbruch W, Wasem J, Ketelhut R, Schmieder RE. [Fixed dose combination of an ARB calcium antagonist lowers blood pressure effectively and improves quality of life]. MMW Fortschr Med 2011; 153 Suppl 1:33-40. [PMID: 21591329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/30/2023]
|
74
|
Bramlage C, Cuneo A, Härtel D, Jung K, Witteck CH, Högel R, Müller G, Bramlage P, Tebbe U. Nierenarterienstenose: Intervention oder medikamentöse Behandlung? Dtsch Med Wochenschr 2011; 136:76-81. [DOI: 10.1055/s-0030-1269442] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
75
|
Bramlage P, Tebbe U. Comments on an acute myocardial infarction study. BRITISH HEART JOURNAL 2010. [DOI: 10.1136/hrt.2010.205989] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
76
|
Ukena C, Mahfoud F, Kindermann M, Gräber S, Kindermann I, Schneider M, Schmieder R, Bramlage P, Volpe M, Thoenes M, Böhm M. Smoking is associated with a high prevalence of microalbuminuria in hypertensive high-risk patients: data from I-SEARCH. Clin Res Cardiol 2010; 99:825-32. [PMID: 20623356 DOI: 10.1007/s00392-010-0194-y] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/23/2010] [Accepted: 06/17/2010] [Indexed: 12/20/2022]
Abstract
BACKGROUND Microalbuminuria (MAU) is a marker of endothelial dysfunction and a predictor of cardiovascular events. The effects of cigarette smoking on the prevalence of MAU in a high-risk population with arterial hypertension are unclear. METHODS The International Survey Evaluating Microalbuminuria Routinely by Cardiologists in patients with Hypertension (I-SEARCH) documented the clinical profile of 20,364 patients with arterial hypertension and cardiovascular risk factors. In this population, 13,690 patients had no history of smoking, 4,057 patients were former smokers and 2,617 patients were current smokers. RESULTS The prevalence of MAU was associated with the smoking status. Consumption of 1-20 cigarettes per day leads to an increase of 6.8% in the prevalence of MAU compared to non-smokers (P < 0.001). Smoking of >20 cigarettes per day was associated with a 12.5% higher prevalence of MAU compared to non-smokers, while former smokers had a 4.7% higher prevalence of MAU. Multivariable analysis revealed that smoking was independently associated with MAU [odds ratio (OR) smoking vs. non-smoking 1.16; 95% confidence interval (CI) 1.01-1.33; P < 0.05]. Particularly, a consumption of >20 cigarettes per day was associated with high odds for MAU (OR 1.33; CI 1.01-1.75; P < 0.05). Interestingly, independently of blood pressure, the use of an angiotensin receptor blocker and an ACE was associated with significantly reduced odds ratio for MAU in the smoking group, while there was no significant association in the non-smoking group. CONCLUSION The prevalence of MAU in hypertensive patients is higher in smokers than in non-smokers with a strong dose dependency.
Collapse
|
77
|
Tschöpe D, Bramlage P, Binz C, Deeg E, Gitt A. Prädiktoren für das Auftreten von Hypoglykämien bei der Behandlung des Typ-2 Diabetes mit einer oralen Mono- oder dualen Kombinationstherapie – Ergebnisse des prospektiven Diabetes Registers (DiaRegis). DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1253753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
78
|
Tschöpe D, Bramlage P, Deeg E, Krekler M, Plate T, Gitt A. Unterschiede in der Behandlung des Typ-2 Diabetes bei Männern und Frauen nach Versagen einer oralen Mono- oder dualen Kombinationstherapie – Ergebnisse des prospektiven Diabetes Registers (DiaRegis). DIABETOL STOFFWECHS 2010. [DOI: 10.1055/s-0030-1253882] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
79
|
Bramlage P, Messer C, Bitterlich N, Pohlmann C, Cuneo A, Stammwitz E, Tebbenjohanns J, Gohlke H, Senges J, Tebbe U. The effect of optimal medical therapy on 1-year mortality after acute myocardial infarction. Heart 2010; 96:604-9. [DOI: 10.1136/hrt.2009.188607] [Citation(s) in RCA: 128] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
80
|
Hasford J, Uricher J, Tauscher M, Bramlage P, Virchow JC. Persistence with asthma treatment is low in Germany especially for controller medication - a population based study of 483,051 patients. Allergy 2010; 65:347-54. [PMID: 19712117 DOI: 10.1111/j.1398-9995.2009.02161.x] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND The objective of the present analysis was to evaluate treatment patterns and persistence with treatment of an unselected patient population with a diagnosis of asthma. METHODS The database of the Bavarian statutory health insurance physician's association (Kassenärztliche Vereinigung) covering 83% of the population was analyzed for an index period from April 2005 to March 2006. Defined daily doses (DDDs) were used to quantify treatment persistence. Results were compared with recent guidelines. RESULTS The prevalence of physician diagnosed asthma in Bavaria was 4.8% in females and 4.5% in males; only 61.4% of these patients (of a total of n = 483,051) received any anti-asthmatic pharmacotherapy; 68.3% received medical care from their general practitioner, and 8.3% from a pulmonologist alone. Most patients (65.1%) received no more than 90 DDDs of controller medication in the index period of 365 days, only about 1% received medication for the complete index period. Long- (40.1%) and short-acting beta(2)-agonists (65.6%) were used more frequently than inhaled corticosteroids (ICS). 52.8% of asthma patients were treated in accordance with guidelines. CONCLUSIONS Persistence of asthma patients with medical treatment is low, especially for controller medication. The discrepancy between current knowledge, guidelines and clinical practice is substantial and may question the value of current guidelines for the treatment of patients with asthma in ambulatory care. In addition, the results of this study cast doubt on the impact of contemporary treatment on the decline of asthma mortality seen in recent years in Germany.
Collapse
|
81
|
Ahrens K, Bramlage P. Importance of a fixed combination of telmisartan and amlodipine for the treatment of hypertension. Drugs Today (Barc) 2010; 46:339-50. [DOI: 10.1358/dot.2010.46.5.1469896] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
82
|
Beyer-Westendorf J, Seitz W, Jabs N, Bramlage P, Kuhlisch E, Julius U, Bornstein S, Schellong S. Nitric oxide and endothelin after lipid apheresis – a pilot study. ATHEROSCLEROSIS SUPP 2009; 10:70-3. [DOI: 10.1016/s1567-5688(09)71815-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
83
|
Zotz R, Kauschat-Brüning D, Bramlage P. Thromboembolierisiko und -prophylaxe internistischer und chirurgischer Patienten im Krankenhaus. Dtsch Med Wochenschr 2009; 134:2163-9. [DOI: 10.1055/s-0029-1241924] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
84
|
Bramlage CP, Kaps C, Ungethüm U, Bramlage P, Koziolek M, Wessels J, Krenn V, Pruß A, Müller GA, Strutz F, Burmester G, Häupl T. Modulatory effects of inflammation and therapy on GDF‐5 expression in rheumatoid arthritis synovium. Scand J Rheumatol 2009; 37:401-9. [DOI: 10.1080/03009740802120010] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
85
|
Bramlage P, Schönrock E, Odoj P, Wolf WP, Funken C. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with candesartan/HCTZ]. MMW Fortschr Med 2008; 150:40. [PMID: 18323344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
|
86
|
Bramlage P, Schönrock E, Odoj P, Wolf WP, Funken C. [Importance of a fixed combination of AT1-receptor blockade and hydrochlorothiazide for blood pressure lowering in cardiac risk patients. A postmarketing surveillance study with Candesartan/HCTZ]. MMW Fortschr Med 2008; 149 Suppl 4:172-181. [PMID: 18402243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/26/2023]
Abstract
BACKGROUND The treatment of arterial hypertension in Germany is, compared to international control rates, not adequate. In particular patients having additional cardiac risk factors like diabetes mellitus, dyslipidemia, increased waist circumference as well as concomitant diseases like myocardial infarction, heart- as well as kidney failure would benefit from an effective antihypertensive therapy. Aim of the present study was therefore to investigate in more detail blood pressure control in patients receiving a fixed combination of 16 mg Candesartan and 12.5 mg hydrochlorothiazide (HCTZ). METHODS The present studywas performed as a non-interventional observational study. Included were patients with previously uncontrolled hypertension with at least one further risk factor. Primary variable was the blood pressure reduction over a time period of 8 weeks; secondary variables were the achievement of blood pressure targets and the tolerability of Candesartan/HCTZ. RESULTS Between August 2006 and February 2007 3,787 patients in 893 physicians' offices in Germany were included. Patients were 62.2 +/- 11.3 years old, 48.1% were female, 97.5% had at least one additional risk factor, 29.8% a cardiovascular event. The risk to die from cardiovascular disease within the next 10 years was 7.4% according to the SCORE Score. By prescribing patients a fixed combination of 16 mg Candesartan/12.5 mg HCTZ a mean blood pressure reduction of -27.2/-13.4 mmHg was achieved (p < 0.001), pulse pressure was reduced by 13.8 mmHg (p <0.001) - both compared to previous therapy. A mean of 83.1% of patients achieved the guideline defined blood pressure targets (140/90 mmHg), 42.9% of patients even 130/80 mmHg. Serious adverse events were extremely rare (0.5%; hypertensive crisis, transitory ischemic attack). CONCLUSION Prescribing patients with previously uncontrolled hypertension a combination of 16 mg Candesartan/12.5 mg HCTZ was tolerable and effective for blood pressure reduction in patients with arterial hypertension and additional risk factors like diabetes mellitus, dyslipidemia and the metabolic syndrome.
Collapse
|
87
|
Bramlage P, Schindler C, Schmidt AC, Bramlage CP, Kirch W. [Recent examples for drug (developments) in primary, secondary and tertiary prevention]. Dtsch Med Wochenschr 2007; 132:2212-6. [PMID: 17926249 DOI: 10.1055/s-2007-991632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
The prevention of disease and the prevention of subsequent disease is one of the main themes in public health as well as in clinical medicine. Besides targeted interventions aiming at the total population (public health) individual steps like life style intervention and use of pharmacotherapy are important components. Taking acute myocardial infarction as an example it is illustrated, how risk factors can be targeted and which new drugs in development have been either just registered or are in late phase III of clinical testing shortly before registration and final approval. In this context it was shown that there are many exciting new options to reduce risk factors. On the other hand there are indications in which new drug development is likely not to contribute to an improvement of the situation (e. g. arterial hypertension) and in which further targeted intervention aiming at physicians (therapeutic pathways, guidelines, point of care research) and patients (life style intervention, compliance) has to be undertaken to improve the efficacy of currently available pharmacotherapy.
Collapse
|
88
|
Hauner H, Hanisch J, Bramlage P, Steinhagen-Thiessen E, Schunkert H, Jöckel KH, Wasem J, Moebus S. Prevalence of Undiagnosed Type-2-Diabetes Mellitus and Impaired Fasting Glucose in German Primary Care: Data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Exp Clin Endocrinol Diabetes 2007; 116:18-25. [PMID: 17926235 DOI: 10.1055/s-2007-985359] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
89
|
Tebbe U, Bramlage P, von Löwis of Menar P, Lawall H, Gaudron P, Lüders S, Klaus A, Lengfelder W, Scholz KH, Maziejewski S, Cuneo A, Hohmann V, Gulba D. [Treatment of the acute coronary syndrome in Germany: experiences in a German cluster of the GRACE registry]. Dtsch Med Wochenschr 2007; 132:2000-5. [PMID: 17882737 DOI: 10.1055/s-2007-985631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
BACKGROUND The acute coronary syndrome (ACS) remains a major cause of mortality and morbidity in the western world. The Global Registry of Acute Coronary Events (GRACE) documents inpatients with all types of ACS and a follow-up at three months in Germany and worldwide. METHODS The data of the German Cluster Detmold were compared with data from the worldwide GRACE registry (31,070 patients). Data from 849 patients with ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI) and unstable angina (UA) were collected from October 2001 to September 2005 in eight participating hospitals in the GRACE2 Cluster Detmold. RESULTS Compared with the worldwide GRACE data the patients in the Cluster Detmold had longer pre-hospital admission times (STEMI patients < 1 h: 13.9 % vs. 17.0 %; p < 0.05); more frequent interventions (PCI 60.1 % vs. 48.7%; p < 0.001) and less thrombolysis (17.9 vs. 42.5%; p < 0.001) in STEMI patients; more frequent use of platelet inhibitors (clopidogrel and ticlopidine, 93.4 % vs. 89.4%; p < 0.001) and unfractionated heparin (69.8 % vs. 36.5; p < 0.001), and less frequent use of low molecular weight heparin (31.1 % vs. 51.2%; p < 0.001); more frequent use of RAS blocking agents (80.2 vs. 66.6, p < 0.001) and beta blockers (87.4 vs. 78.8, p < 0.001) and less frequent use of lipid lowering agents (23.5 vs. 72.5%; p < 0.001). CONCLUSIONS Current management of ACS in Germany closely follows the recommendations of the German society of Cardiology. Differences in practice may account for the observed substantially lower event rates in Germany during hospitalization, but there is still room for improvement in the pre-hospital phase und in the degree to which pharmacotherapy is used for secondary prevention.
Collapse
|
90
|
Scholze J, Lilienthal W, Bramlage P. [Cardiometabolic high risk patients with abdominal obesity. Frequency and risk factor profile in primary care]. MMW Fortschr Med 2007; 149:40. [PMID: 17918461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
|
91
|
Diener HC, Röther J, Rosin L, Bramlage P. Niedermolekulare Heparine zur Thromboseprophylaxe nach ischämischem Schlaganfall. AKTUELLE NEUROLOGIE 2007. [DOI: 10.1055/s-2007-970956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
92
|
Tebbe U, Messer C, Stammwitz E, The GS, Dietl J, Bischoff KO, Schulten-Baumer U, Tebbenjohanns J, Gohlke H, Bramlage P. [Reduction of in-hospital mortality and improved secondary prevention after acute myocardial infarction. First results from the registry of secondary prevention after acute myocardial infarction (SAMI)]. Dtsch Med Wochenschr 2007; 132:1559-66. [PMID: 17628839 DOI: 10.1055/s-2007-984934] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND AND OBJECTIVE In hospital mortality of acute myocardial infarction (AMI) has been reduced due to the availability of better therapeutic strategies. But there is still a gap between mortality rates in randomised trials and daily clinical practice. Thus, it was aim of the present registry to document the course and outcome of patients with AMI and to improve patient care by implementing recent guidelines. PATIENTS AND METHODS In a nationwide registry study in hospitals in Germany with a cardiology unit or an internal medicine department data on consecutive patients were recorded for six to twelve months at admission, discharge and during a follow-up of one year. RESULTS From 02/2003 until 10/2004 a total of 5,353 patients with acute myocardial infarction (65.7 % male, mean age of 67.6 +/- 17.7 years; 55.1 % of them with ST elevation myocardial infarction (STEMI) were included in the registry. Of the patients with STEMI, 76.6 % underwent acute intervention, 37.1 % had thrombolysis, 69.7 % percutaneous transluminal coronary angioplasty (PTCA). 40.0 % of those with non-Stemi (NSTEMI) had an acute intervention, 6.6 % thrombolysis, 73.5 % PTCA. Recommended secondary prevention consisted of ASS (93.2 %), beta-blockers (93.0 %), CSE-inhibitors (83.5 %), ACE-inhibitors (80.9 %) and clopidogrel (74.0 %). In-hospital mortality was 10.5 % (STEMI) and 7.4 % (NSTEMI). CONCLUSION The 9 % mortality among patients with acute myocardial infarction treated in the hospitals participating in the SAMI registry is low compared to that in similar collectives. The high number of patients who had thrombofibrinolysis and coronary interventions as well as the early initiation of drug therapy contributed to these results. Medical treatment in the prehospital phase of these patients remains still insufficient and to a substantial extent contributes to the mortality of acute myocardial infarction.
Collapse
|
93
|
Schmidt AC, Bramlage P, Lichtenthal A, Eckert M, Scholze J. Socio-economic status and the therapeutic effectiveness of antihypertensive treatment--the design of the LEO study. Curr Med Res Opin 2007; 23:1987-95. [PMID: 17637203 DOI: 10.1185/030079907x226078] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVE The risk of arterial hypertension and subsequent cardiovascular disease morbidity and mortality increases with low socio-economic status (SES). Even small differences in blood pressure, whether untreated or despite treatment, account for this substantial difference. Most of the increased risk in the low socio-economic group is due to traditional cardiovascular risk factors such as overweight and obesity, alcohol consumption and a sedentary life style. Intense treatment of arterial hypertension has been shown to overcome these prognostic inequalities. Therefore, drugs with high efficacy, optimal treatment adherence and a low potential for drug-related side effects are needed in order to reduce the cardiovascular risk burden of patients with a low SES. The angiotensin receptor blocker (ARB) olmesartan will be used to investigate the effectiveness of this drug in different socio-economic classes. RESEARCH DESIGN AND METHODS The LEO (Long-term Effectiveness of Olmesartan in different Socioeconomic groups) study is a large observational long-term study which has been set up to test the effectiveness of olmesartan within this context. The study has a matched-pairs design (1403 patients in both the low and the high socio-economic classes). MAIN OUTCOME MEASURES The LEO study will test whether this regimen can reduce the SES-related difference in long-term blood pressure control and compliance in the low SES population. CONCLUSIONS The study may generate valuable information about the antihypertensive effectiveness of olmesartan alone or in combination with hydrochlorothiazide in different socio-economic classes. It will further test whether the drug helps to reduce the inherent inequalities in cardiovascular prognosis between different socio-economic groups. CURRENT STATUS The study commenced in July 2007. Results are anticipated in December 2008.
Collapse
|
94
|
Hauner H, Bramlage P, Hanisch J, Schunkert H, Steinhagen-Thiessen E, Wasem J, Jöckel KH, Moebus S. Bisher unerkannter Diabetes mellitus und erhöhte Nüchternglukose in der primärärztlichen Versorgung: Das German Metabolic and Cardiovascular Risk Project (GEMCAS). DIABETOL STOFFWECHS 2007. [DOI: 10.1055/s-2007-982459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
95
|
Schmieder RE, Schrader J, Zidek W, Tebbe U, Bramlage P, Paar WD, Böhm M. Subklinische Albuminurie, Mikroalbuminurie und Proteinurie - akzeptierte kardiovaskuläre Risikomarker? Dtsch Med Wochenschr 2006; 131:2665-71. [PMID: 17109277 DOI: 10.1055/s-2006-956273] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
96
|
Bramlage P, Böcking W, Kirch W. Klinische Pharmakologie: Erkenntnisgewinn zu Arzneimitteln nach der Zulassung. Dtsch Med Wochenschr 2006; 131:1485-7. [PMID: 16794982 DOI: 10.1055/s-2006-946607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
97
|
Bramlage P, Mühlen I, Randeva H, Spanswick D, Lehnert H. Cardiovascular Risk Management by Blocking the Endocannabinoid System. Exp Clin Endocrinol Diabetes 2006; 114:75-81. [PMID: 16570237 DOI: 10.1055/s-2006-923885] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
The specific blockade of endocannabinoids at the level of the cannabinoid receptor 1 (CB (1) receptor) is a new therapeutic option to reduce body weight and manage cardiovascular risk. Although clinical trials are underway to document the safety and efficacy of this approach, much is still unknown about this endogenous system. Endocannabinoids and their receptors are expressed in the central nervous system as well as in the periphery and regulate the central neural circuits for food uptake and peripheral metabolic circuits. Within the context of food uptake, the stimulation of the CB (1) receptor with Delta (9)-tetrahydrocannabinol (Delta (9)-THC) enhances food consumption, while its blockade with receptor antagonists is an emerging relevant therapeutic means to reduce body weight. Rimonabant is the first of a new class of drugs that interferes with the endocannabinoid system by blocking the CB (1) receptor. In recent clinical studies, a substantial reduction in body weight and waist circumference was associated with an improvement of the cardiovascular risk profile. In particular, increased HDL cholesterol, decreased serum triglycerides and improved insulin sensitivity were observed. Further research will serve to establish the role of these compounds in cardiovascular risk management.
Collapse
|
98
|
Bramlage CP, Häupl T, Kaps C, Bramlage P, Müller GA, Strutz F. Bone Morphogenetic Proteins im Skelettsystem—. Z Rheumatol 2005; 64:416-22. [PMID: 16184350 DOI: 10.1007/s00393-005-0665-0] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2004] [Accepted: 09/06/2004] [Indexed: 01/08/2023]
Abstract
Bone morphogenetic proteins (BMPs) belong to the transforming growth factor-beta superfamily. Their potential for organ and tissue regeneration and repair has been intensively investigated in recent years. Studies on fetal development have demonstrated the important role of these proteins for the development and differentiation of different organs. Miss-expression or mutation of BMPs may lead to severe abnormalities or even abortion. However, a regenerative potential has also been recognized for the adult organism. BMPs support fracture healing and may contribute to treatment of joint diseases. Thus, BMP-7 is one of the first BMPs approved for clinical application in non-unions of bone fractures resistant to conventional therapy. In degenerative and inflammatory joint diseases, experimental data suggest a decrease of BMP expression in cartilage tissue. Therefore, BMPs could be promising therapeutic candidates in these diseases, although more detailed analyses are necessary. In this review we will focus on bone morphogenetic proteins and discuss present and putative future clinical applications.
Collapse
|
99
|
Strutz F, Bramlage P, Paar WD. Effect of three months' treatment with irbesartan on blood and pulse pressure of hypertensive type 2 diabetic patients: open, observational study in 31,793 patients. Curr Med Res Opin 2005; 21:1433-40. [PMID: 16197662 DOI: 10.1185/030079905x61811] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES In hypertensive diabetics the cardiovascular risk is substantially increased. Therefore, an effective reduction of both blood pressure and pulse pressure is of particular importance for these patients. The aim of the prospective observational study in hypertensive type 2 diabetics was to assess the effect of a switch from the previous antihypertensive therapy to the angiotensin-II-receptor antagonist irbesartan (alone or in combination with HCTZ) on the reduction of blood pressure and pulse pressure, the reduction of diabetic nephropathy (microalbuminuria), and tolerability. METHODS 8714 general practitioners included 31,793 type 2 diabetics aged at least 18 years in an open observational study. After inclusion in to the study the patients received irbesartan 300 mg as monotherapy or in combination with hydrochlorothiazide 12.5 mg (HCTZ). Main outcome measures for efficacy were the reduction of systolic (SBP) and diastolic (DBP) blood pressures, reduction of pulse pressure, and blood pressure responder (reduction in DBP > or = 10 mmHg or diastolic < 90 mmHg), diastolic normalization (DBP < 90 mmHg) and overall normalization rates (SBP < 140 mmHg and DBP < 90 mmHg) after 3 months. Further outcome measures included the reduction of microalbuminuria or proteinuria, and adverse events (AEs) as a measure of tolerability. RESULTS Thirty-eight per cent of patients received irbesartan 300 mg and 61% irbesartan in combination with HCTZ. Mean systolic blood pressure was reduced by 22.5 mmHg, diastolic blood pressure by 10.7 mmHg (baseline values: 160.2 and 93.2 mmHg). Pulse pressure fell on average by 11.6 mmHg. 83.4% of the patients were responders, with an overall normalization rate of 42.7% (SBP < 140 mmHg and DBP < 90 mmHg), respectively 73.8% (DBP < 90 mmHg). The antihypertensive benefit was achieved irrespective of the previous medication. Mean albuminuria decreased by about 27.7 mg/L. Only 0.3% of patients experienced adverse events. CONCLUSIONS In type 2 diabetics with hypertension and either uncontrolled or no previous antihypertensive therapy a change to treatment with irbesartan or irbesartan/HCTZ for 3 months resulted in a distinct reduction of systolic and diastolic blood pressures, with concomitant effective reductions of pulse pressure and microalbuminuria.
Collapse
|
100
|
Sharma AM, Bramlage P, Kirch W. [Good blood pressure control even in overweight patients]. MMW Fortschr Med 2005; 147:48. [PMID: 15966172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/03/2023]
|